Merck to partner with Google Cloud on AI initiatives in a major move aimed at expanding artificial intelligence across drug development, manufacturing, regulatory operations and commercial teams.
The partnership was announced at Google’s Cloud Next conference in Las Vegas. Merck said it could invest as much as $1 billion with Google over several years to support AI infrastructure, engineering talent and licensing for Google’s Gemini Enterprise platform.
The agreement builds on existing work between the two companies and signals a deeper long-term collaboration.
Merck to Partner With Google Cloud on AI Initiatives Across Core Operations
Executives from both companies said Google Cloud engineers will work directly with Merck teams as part of the expanded partnership.
Dave Williams, Merck’s chief information and digital officer, said the company is not simply purchasing AI usage capacity, but investing in a broader set of tools and capabilities.
He said he could “easily” see Merck investing $1 billion over the next several years, adding that the collaboration could last at least a decade, although no fixed timeline has been set.
The companies said the partnership will focus on deploying AI across research, regulatory work, manufacturing and commercial functions.
Focus on Faster Drug Development
Both companies described the deal as a way to help accelerate the process of developing medicines.
Google Cloud CEO Thomas Kurian said the company has long wanted AI to play a positive role in society, including helping people find cures for illnesses.
He said Merck brings deep domain expertise, while Google Cloud provides AI tools, platforms and cybersecurity capabilities to support that work.
How Merck Is Already Using AI
Williams said Merck plans to apply AI throughout the drug development lifecycle.
That includes running computerized simulations of laboratory experiments and helping speed regulatory processes.
He also said the company has already used AI for around two years to help prepare sections of clinical study reports, with positive results.
According to Williams, Merck has also used Google technology to cut the time and cost of compiling reimbursement dossiers for new medicines by half in many countries.
From Pilot Projects to Global Scale
Williams emphasized that the effort has already moved beyond early testing.
He said Merck is currently submitting dossiers in markets using the new capability and is now expanding the system globally.
With Merck to partner with Google Cloud now official, the collaboration reflects how pharmaceutical companies are increasing investment in AI initiatives tied to real operational outcomes.
Don’t miss out on our latest news—follow us for the latest AI news, breakthroughs